Uncertain Future For Otelixizumab In Type 1 Diabetes After Phase III Failure
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
GlaxoSmithKline and Tolerx announced March 11 that their humanized anti-CD3 monoclonal antibody, otelixizumab failed to meet the primary endpoint in the Phase III DEFEND-1 trial for type 1 diabetes, and they were halting recruitment and dosing in another Phase III trial, DEFEND-2, while they review the DEFEND-1 results.